Free Trial
NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

Acumen Pharmaceuticals logo
$1.26 -0.01 (-0.79%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Key Stats

Today's Range
$1.24
$1.26
50-Day Range
$1.07
$1.68
52-Week Range
$0.86
$3.36
Volume
12,925 shs
Average Volume
332,728 shs
Market Capitalization
$76.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33
Consensus Rating
Buy

Company Overview

Acumen Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

ABOS MarketRank™: 

Acumen Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 363rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Acumen Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Acumen Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.56) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acumen Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acumen Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acumen Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.98% of the float of Acumen Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acumen Pharmaceuticals has recently decreased by 7.28%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Acumen Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Acumen Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.98% of the float of Acumen Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acumen Pharmaceuticals has recently decreased by 7.28%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Acumen Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Acumen Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for ABOS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.30% of the stock of Acumen Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acumen Pharmaceuticals' insider trading history.
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Stock News Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
Earnings Scheduled For August 12, 2025
See More Headlines

ABOS Stock Analysis - Frequently Asked Questions

Acumen Pharmaceuticals' stock was trading at $1.72 at the beginning of the year. Since then, ABOS shares have decreased by 26.7% and is now trading at $1.26.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.14.
Read the conference call transcript
.

Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

Top institutional investors of Acumen Pharmaceuticals include Franklin Resources Inc. (5.08%), Geode Capital Management LLC (0.65%), Y Intercept Hong Kong Ltd (0.41%) and Marshall Wace LLP (0.23%). Insiders that own company stock include Ra Capital Management, LP, Daniel Joseph Oconnell, Matt Zuga, Eric Siemers, Russell Barton, Derek M Meisner and Jeffrey L Ives.
View institutional ownership trends
.

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA) and Netflix (NFLX).

Company Calendar

Last Earnings
8/12/2025
Today
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABOS
CIK
1576885
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$4.00
Potential Upside/Downside
+402.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$102.33 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-73.93%
Return on Assets
-57.71%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
8.02
Quick Ratio
8.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.03 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
60,573,000
Free Float
54,940,000
Market Cap
$76.32 million
Optionable
Optionable
Beta
0.14
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ABOS) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners